Annexon, Inc. (NASDAQ: ANNX) is among the 12 hot penny stocks to invest in right now, with strong analyst confidence in its vonaprument advancement. Wells Fargo raised its price target on ANNX from $14 to $27, citing an increased probability of success in the Phase 3 trial to 55%.

In Q3 2025, Annexon reported a net loss of $54.9 million, driven by R&D expenses of $49.7 million for vonaprument’s Phase 3 trial. However, G&A expenses decreased, and the company closed the quarter with $188.7 million in cash, providing runway into early 2027.

Annexon is focused on developing complement inhibitors targeting neuroinflammation in various medical fields, including autoimmunity, neurodegeneration, and ophthalmology. The company’s neuroinflammation platform is making progress, with EU Marketing Authorization Application submission for tanruprubart in January 2026.

While ANNX shows investment potential, other AI stocks may offer greater upside with less downside risk. For those seeking undervalued AI stocks, a free report on the best short-term AI stock is recommended. No disclosures were made.

Read more at Yahoo Finance: Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement